TL;DR — Dasatinib plus quercetin has early human senolytic studies, but dasatinib is a potent leukemia drug with serious hematologic and infectious risks and no role in self-experimentation. Evidence tierTNiC's A/B/C grading of how strong the human research is behind a compound. Full glossary →: C. This is an educational research module—not a self-treatment recommendation.
What Dasatinib does
Dasatinib is a prescription tyrosine-kinase inhibitor approved for leukemia (it targets BCR-ABL and Src-family kinases). In longevity it is the "D" of the D+Q senolytic protocol: pulsed together with the flavonoid quercetin, it selectively kills senescent "zombie" cells by disabling the pro-survival kinase networks those cells depend on. Small early human pilots (idiopathic pulmonary fibrosis, diabetic kidney disease) report reduced senescent-cell markers after short D+Q courses. But dasatinib is a potent chemotherapeutic with serious hematologic, bleeding, and infection risks — it has no role in unsupervised self-experimentation.
Primary hallmarks targeted: Cellular senescence (senolysis) · Chronic inflammation (SASPSenescence-Associated Secretory Phenotype — the inflammatory cocktail of cytokines, proteases, and growth factors secreted by senescent (zombie) cells. Full glossary → reduction)
Early-phase human pilots of D+Q show reduced senescent-cell burden markers, and the senolytic mechanism is well characterized preclinically — but these are tiny, short studies in disease populations with no lifespan/healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary → endpoint, against a drug with a serious adverse-event profile.
Mechanism and biological context
Senescent cells resist apoptosis by leaning on "senescent-cell anti-apoptotic pathways" (SCAPs) — including Src-family and ephrin-dependent kinase signaling. Dasatinib inhibits those kinases, removing the survival crutch so the senescent cell undergoes apoptosis; quercetin covers a complementary SCAP set (BCL-2/BCL-xL, PI3K), which is why the two are dosed together rather than alone. Crucially, this is a hit-and-run pulse (a couple of days, intermittently), not daily dosing — senolyticsCompounds that selectively destroy senescent (zombie) cells that accumulate with age and secrete inflammatory signals. Full glossary → only need to be present long enough to trigger clearance. Clearing senescent cells lowers the inflammatory SASP those cells secrete.
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| SFK/ephrin kinase inhibition | Disables senescent-cell survival signaling | Cellular senescence |
| Senolytic apoptosis | Selective death of senescent cells | Cellular senescence |
| Pulsed dosing | Intermittent hit-and-run, not daily | Reduces cumulative toxicity vs. chronic use |
| SASP reduction | Fewer inflammatory secretions after clearance | Chronic inflammation |
The senolytic mechanism is among the best-developed in the field; what is missing — and what the risk profile makes hard to obtain casually — is human outcome data, which is exactly why this stays Tier C and physician-only.
Evidence summary
| Study | Source | Year | Citation |
|---|---|---|---|
| Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. | EBioMedicine | 2019 | PMID 31542391 |
| Senolytic drugs: from discovery to translation. | Journal of internal medicine | 2020 | PMID 32686219 |
| Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. | EBioMedicine | 2023 | PMID 36857968 |
← Swipe for more columns →
Evidence verdict: Tier C. These records establish that the topic is represented in peer-reviewed literature. Read each design and population before applying its result; adjacent evidence is not interchangeable with a dedicated trial.
Where dasatinib disappoints
- The human evidence is tiny and endpoint-free. The D+Q pilots are small, short, in diagnosed disease populations, and measure senescent-cell markers — not lifespan, healthspan, or any hard clinical outcome. - The risk is real chemo risk. Dasatinib is a leukemia drug with hematologic suppression, bleeding, pleural effusion, and infection risk — the benefit/risk for a healthy person self-experimenting is upside-down. - Senolysis is proven preclinically, not in outcomes. "Clears zombie cells in a dish and in mice" is not "makes people healthier"; that translation step is exactly what's missing.
What would change this grade. Dasatinib is C — strong preclinical senolytic mechanism, only feasibility/marker human pilots. Powered, controlled senolytic trials with a real clinical endpoint would move it; the serious adverse-event profile keeps it physician-only regardless of grade.
Is Dasatinib a fit?
Is there a defined goal, a plausible deficiency/indication, and a measurable endpoint?
Consider a time-bounded, monitored trial at the evidence-aligned dose.
Defer it; adding compounds without a decision rule increases cost and interaction risk.
Prescription/research-only: specialist oversight is mandatory.
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Practical standard |
|---|---|
| Dose | Prescription oncology drug |
| Timing | specialist-directed |
| Trial length | 8–12 weeks unless the cited indication specifies otherwise |
| Stop rule | Adverse effects, worsening labs, or no meaningful response at review |
A disciplined trial
- Record the exact product, form, and dose.
- Change one major variable at a time.
- Define the endpoint and stop rule before starting.
- Do not extrapolate a disease-population dose to healthy self-experimentation.
Monitoring
| Monitor | When | Why |
|---|---|---|
| Goal-specific symptom or performance metric | Baseline and weekly | Detect a practical response |
| Medication and adverse-effect review | Baseline and each change | Catch interactions early |
| Relevant clinician-selected labs | Baseline and 8–12 weeks | Verify safety and direction |
Question
Vague longevity hope
Review
Indefinite
Question
Specific measurable goal
Review
8–12 week decision point
Safety and red flags
Do not confuse availability with safety
This intervention is prescription-only or experimental. Do not source, dose, or combine it without an appropriately qualified clinician.
Evidence in one population does not establish safety in pregnancy, organ impairment, or polypharmacy. Product quality and dose accuracy matter.
Who should skip dasatinib
- Anyone without a prescription and specialist oversight — this is a chemotherapeutic, not a supplement; unsupervised use is genuinely dangerous. - Anyone on anticoagulants/antiplatelets — dasatinib causes thrombocytopenia and platelet dysfunction; bleeding risk is additive and serious. - Anyone who could get the senolytic goal from fisetin instead — an OTC senolytic without a chemo drug's risk is the safer self-directed route.
Synergies and antagonists
Pairs well with:
| Partner | Integration rationale |
|---|---|
| quercetin | The validated pairing — quercetin covers the BCL-2/PI3K survival pathways dasatinib doesn't, and D+Q is the benchmark senolytic regimen in the human pilots. |
| fisetin | The OTC-only alternative: fisetin has a standalone senolytic signal without a prescription chemotherapeutic — the safer self-directed route for most people. |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| CYP3A4 inhibitors (azole antifungals, grapefruit, some antibiotics) | Raise dasatinib levels into a more toxic range | Physician must manage; never combine unmonitored |
| Anticoagulants / antiplatelets | Additive bleeding on top of dasatinib-induced thrombocytopenia | Specialist oversight only |
| QT-prolonging drugs / acid-reducers | QT risk; acid reducers cut dasatinib absorption | Coordinate all co-medications with the prescriber |
Start with the smallest stack that answers the question. SynergyWhen two compounds together produce greater effect than either alone. Full glossary → is a mechanistic hypothesis unless a combination trial demonstrates it.
Personal results template
My Dasatinib results log
| Date | Dose / timing | Primary endpoint | Safety notes | Decision |
|---|---|---|---|---|
| YYYY-MM-DD | Baseline | — | — | Start / defer |
| YYYY-MM-DD | Week 4 | — | — | Continue / adjust / stop |
| YYYY-MM-DD | Week 12 | — | — | Keep / stop |
← Swipe for more columns →
Success rule: a meaningful, repeatable improvement in the preselected endpoint without unacceptable adverse effects or lab movement.
References
- Justice JN et al. Senolytics decrease senescent cells in humans. EBioMedicine (2020). PMID 31542391
- PMID 32686219
- PMID 36857968
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.